Prospective study of HBV reactivation in patients with chronic HCV infection, treated with direct acting antivirals

Prospective study of HBV reactivation in patients with chronic HCV infection, treated with direct acting antivirals - HBV reactivation survey in DAA therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024019

Enrollment

300

Registered

2017-12-31

Start date

2016-08-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease with HCV

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated with DAA therapy. and With more than one of HBV serum markers; HBsAg, anti-HBc, anti-HBs.

Exclusion criteria

Exclusion criteria: Negative for all of HBV serum markers; HBsAg, anti-HBc, anti-HBs. Patients who continue the other viral therapy. Patients cannot be checked regularly. Less than 15 years old. Doctor recognize a patient unsuitable to enroll the study.

Design outcomes

Primary

Measure	Time frame
Prevalence of HBV reactivation	—

Secondary

Measure	Time frame
Treatment of HBV reactivation Human factors associated with HBV reactvation Viral factors associated with HBV reactivation	—

Countries

Japan

Contacts

Public ContactAkihiro TAMORI

Osaka City University Graduate School of Medicine Hepatology

atamori@med.osaka-cu.ac.jp06-6645-2292

Outcome results